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The IL-1 receptor family includes 10 members, 
which contain IgG-like segments in the extracel-
lular domain and a cytoplasmic toll/IL-1 receptor 
intracellular domain that is found in other Toll-
like receptors (TLRs; Dinarello, 2009). The 
proinflammatory cytokines IL-1 and IL-1 
bind the IL-1R type I (IL-1RI), leading to ac-
tivation of NF-B, the mitogen-activated pro-
tein kinase (MAPK), and certain IFN regulatory 
factors (IRFs; Fujita et al., 1989; Rivieccio et al., 
2005). IL-1RI is constitutively expressed in most 
cell types (Dinarello, 1996), and it is the most 
studied member of the IL-1R family (Dinarello, 
1996, 2009). Although the role of IL-1 in sterile 
inflammation, such as rheumatoid arthritis, 
gout, or autoinflammatory syndromes (Dinarello, 
2009), has been extensively studied, its role in 
nonsterile inflammatory conditions, such as in-
flammatory bowel disease, has not been clearly 
defined (Bresnihan et al., 1998; Hoffman et al., 
2004). Despite its role in inflammation, IL-1 sig-
naling has been reported to protect mice from 
intestinal damage after Citrobacter rodentium infec-
tion (Lebeis et al., 2009) and from dextran sul-
phate sodium (DSS)–induced colitis (Kojouharoff 
et al., 1997; Lebeis et al., 2009). In contrast, 
administration of anti–IL-1 antibody improved 
DSS-induced colitis (Arai et al., 1998), and 
mice deficient in the NLRP3 inflammasome, a 
caspase-1–activating complex which regulates 
IL-1 and IL-18 maturation, are relatively resis-
tant to intestinal inflammation induced in this 
model (Bauer et al., 2010). In this paper, we 
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The interleukin 1 receptor (IL-1R) and the Toll-like receptors (TLRs) are highly homologous 
innate immune receptors that provide the first line of defense against infection. We show 
that IL-1R type I (IL-1RI) is essential for TLR9-dependent activation of tumor necrosis 
factor receptor-associated factor 3 (TRAF3) and for production of the antiinflammatory 
cytokines IL-10 and type I interferon (IFN). Noncanonical K63-linked ubiquitination of 
TRAF3, which is essential for type I IFN and IL-10 production, was impaired in Il1r1/ 
CD11c+ dendritic cells. In contrast, degradative ubiquitination of TRAF3 was not affected in 
the absence of IL-1R1 signaling. Deubiquitinating enzyme A (DUBA), which selectively 
cleaves K63-linked ubiquitin chains from TRAF3, was up-regulated in the absence of IL-1R1 
signaling. DUBA short interference RNA augmented the TLR9-dependent type I IFN re-
sponse. Mice deficient in IL-1RI signaling showed reduced expression of IL-10 and type I 
IFN and increased susceptibility to dextran sulphate sodium–induced colitis and failed to 
mount a protective type I IFN response after TLR9 ligand (CpG) administration. Our data 
identifies a new molecular pathway by which IL-1 signaling attenuates TLR9-mediated 
proinflammatory responses.
© 2010 González-Navajas et al.  This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Il1r1/ mice showed an impaired ability to recover from 
DSS-induced colitis and kept losing weight after DSS re-
moval at day 7 (Fig. S1 A). In previous studies, administra-
tion of unmethylated CpG, a synthetic ligand for TLR9, was 
shown to attenuate DSS-induced colitis in mice, mainly via 
the induction of a type I IFN response (Rachmilewitz et al., 
2002; Katakura et al., 2005). Accordingly, i.p. injection of 
CpG, before DSS administration, efficiently ameliorated 
the severity of colonic inflammation in WT mice (Fig. 1 A). 
In contrast, CpG administration resulted in a higher DAI 
score and further increased mortality in Il1r1/ mice (Fig. 1, 
A and B). Histological analysis of the colonic tissues from the 
DSS-treated mice revealed that both WT and Il1r1/ mice 
developed  mucosal  inflammation  with  epithelial  ulcer-
ations, crypt loss, depletion of goblet cells, and marked in-
filtration of mononuclear cells in the colonic lamina propria 
(Fig. 1 C). The extent of epithelial damage was more se-
vere in Il1r1/ mice in which DSS administration caused 
almost complete ablation of the colonic epithelium (Fig. 1 C). 
describe a novel mechanism by which IL-1RI signaling mod-
ulates the TLR-dependent inflammatory response. We show 
that IL-1RI signaling down-regulates the expression of deubiq-
uitinating enzyme A (DUBA) and consequently enhances   
the Lys63-linked ubiquitination of TNF receptor-associated 
factor 3 (TRAF3), which is necessary for the transcription of 
antiinflammatory cytokines.
RESULTS AND DISCUSSION
Genetic and pharmacologic targeting of IL-1RI exacerbates 
DSS-induced colitis
Mice exposed to orally delivered DSS develop acute colitis, 
displaying diarrhea, rectal bleeding, and weight loss. To better 
define how IL-1R contributes to colonic homeostasis, we 
exposed C57BL/6 (B6 and WT) and Il1r1/ mice to DSS 
in the drinking water ad libitum. Surprisingly, Il1r1/ mice 
were more susceptible to DSS colitis, as indicated by a higher 
disease activity index (DAI) score and an increased mortality 
compared with WT mice (Fig. 1, A and B). Furthermore, 
Figure 1.  Il1r1/ mice are more susceptible to DSS-induced colitis than WT mice. (A) DAI score in WT and Il1r1/ mice. Mice were given DSS 
(2%) in their drinking water for 7 d with or without pretreatment with CpG oligonucleotides (10 µg/mouse) 2 h before DSS administration. (B) Survival of 
WT and Il1r1/ mice treated as described in A. (C) Hematoxylin and eosin staining of colon sections from untreated mice or WT and Il1r1/ on day 7 of DSS 
treatment. Bar, 50 µm. (D) Quantitative PCR analysis of pro- and antiinflammatory mediators in colonic homogenates from WT and Il1r1/ mice on day 7 of 
DSS treatment. (A–D) Data are representative of four different experiments (n = 6). Error bars represent mean ± SEM. ns, not significant. *, P < 0.05; **, P < 0.01.JEM VOL. 207, December 20, 2010  2801
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obtained from each group after 7 d of DSS, with or without 
CpG treatment. CpG administration decreased the mRNA 
levels of inflammatory cytokines, such as TNF and IL-6, in 
WT but not in Il1r1/ mice (Fig. 1 D). More importantly,   
the administration of CpG resulted in increased mRNA   
levels of the antiinflammatory mediators IL-10 and IFN-  
in the colonic tissues obtained from WT mice but not in those 
obtained from Il1r1/ mice (Fig. 1 D).
Importantly, although the administration of CpG highly re-
duced the DSS-induced damage in WT mice, it did not 
have any beneficial effect on colonic inflammation in Il1r1/ 
mice (Fig. 1 C).
To determine potential causes for the differences in colitis 
severity and the differential response to CpG in WT versus 
Il1r1/ mice, we measured the relative mRNA levels of 
pro- and antiinflammatory cytokines in colonic homogenates 
Figure 2.  Il1r1/ mice have impaired IL-10 and type I IFN response. (A) Cytokine levels in serum of WT and Il1r1/ mice 2 h after i.v. administra-
tion of 50 µg CpG oligonucleotides or vehicle (C). Data are representative of two independent experiments (n = 4). (B) Cytokine levels in supernatants 
from WT and Il1r1/ CD11c+ BMDCs 24 h after stimulation with 10 µg/ml CpG, 10 µg/ml Poly(I:C), or vehicle (C). (C) WT BMDCs were incubated with 
isotype control antibody, IL-1RI blocking antibodies, or IL-1 neutralizing antibody for 2 h. Cells were then stimulated with CpG for 24 h and cytokine 
levels were determined in the supernatants. (D) Effect of IL-1 prestimulation on cytokine production. WT BMDCs were cultured in the presence of 0, 1, 
or 10 ng/ml of recombinant IL-1 for 12 h. Cells were then washed and restimulated or not with 10 µg/ml CpG for 24 h, and the levels of cytokines were  
determined in the supernatants. (B–D) Data are representative of three different experiments. Error bars represent mean ± SEM. ns, not significant.  
*, P < 0.05; **, P < 0.01; ***, P < 0.001.2802 IL-1RI dampens DUBA | González-Navajas et al.
PGE2, in turn, was reported to inhibit mucosal inflammation 
in DSS-induced colitis in mice and rats (Kabashima et al., 
2002; Nitta et al., 2002). Similarly, pretreatment with a low 
dose of IL-1 was also shown to suppress colonic inflamma-
tion in rabbits via the production of PGE2 (Cominelli et al., 
1990). Nevertheless, as type I IFN production by CD11c+ 
DCs is partially responsible for CpG-dependent attenuation 
of colitis in WT mice in this model (Katakura et al., 2005; 
Abe et al., 2007), we reasoned that the impaired ability to 
produce type I IFN in response to TLR9 stimulation in 
Il11r/ mice facilitated colonic inflammation. Indeed, the 
administration of recombinant mouse (rm) IFN- ameliorated 
the severity of DSS-induced colitis (Fig. S2 A) and suppressed 
the inflammatory cytokine production in the colonic tissue of 
Il1r1/ mice (Fig. S2 B).
Our data so far indicate a defect in IL-10 and type I IFN 
production in the colonic tissues of Il1r/ mice. To explore 
whether these mice have a reflection of a systemic defect, we 
injected CpG i.v. and measured the serum levels of these cyto-
kines. Indeed, we observed lower levels of these antiinflam-
matory cytokines in the serum of Il1r/ as compared with 
WT mice (Fig. 2 A). Furthermore, BM-derived DCs (BMDCs) 
from Il11r/ mice produced lower levels of IL-1, IL-10, 
A recombinant form of IL-1R antagonist (IL-1Ra), also 
known as anakinra, is currently used in the treatment of 
rheumatoid arthritis and several human autoinflammatory dis-
eases (Dinarello, 2009). To study the impact of IL-1Ra on the 
course of experimental colitis, we treated WT mice i.p. with 
either anakinra (1 mg/mouse, twice a day) or vehicle during the 
course of DSS administration. Blocking IL-1 activity with 
anakinra enhanced the severity of DSS-induced colitis in WT 
mice, as indicated by a higher DAI score and a more severe 
epithelial damage (Fig. S1, B and C). Anakinra treatment also 
resulted in increased levels of proinflammatory cytokines and 
reduced IFN- production in supernatants from ex vivo–
cultured colonic tissues (Fig. S1 D). Collectively, these results 
correlate with the phenotype of intestinal inflammation ob-
served in Il1r1/ mice and suggest that IL-1 signaling sup-
ports colonic homeostasis and attenuates colonic inflammation 
in this model.
Il1r/ mice display impaired production of IL-10 and type I IFN
Several mechanisms may be responsible for the increased 
susceptibility of Il1r1/ mice to DSS-induced colitis. IL-1 
promotes prostaglandin E2 (PGE2) production via the induc-
tion of COX-2 (Mizel et al., 1981; Martin et al., 1994). 
Figure 3.  Il1r1/ BMDCs display impaired IRF3 and IRF7 responses. (A) Electrophoretic mobility shift assay (EMSA) analysis of NF-B activation in 
WT and Il1r1/ BMDCs after CpG stimulation (10 µg/ml) for the indicated time periods. (B) BMDCs from WT and Il1r/ mice were stimulated with 10 µg/ml 
CpG for 3 h, followed by RNA isolation and quantitative PCR analysis using GAPDH expression as internal reference. (C) Immunoblot analysis of MAPK 
activation in BMDCs from WT and Il1r1/ stimulated with 10 µg/ml CpG oligonucleotides for the indicated time periods. (D) Immunoblot analysis of IRF3 
and IRF7 in nuclear extracts of BMDCs from WT and Il1r1/ mice stimulated as in C. (E) Baseline levels of IRF3 and IRF7 in nuclear extracts from freshly 
isolated unstimulated splenocytes from WT and Il1r1/ mice. (F) WT BMDCs were left unstimulated (0) or were stimulated with 10 ng/ml of recombinant 
IL-1, 10 µg/ml CpG, or both for the indicated time periods. Nuclear extracts were then isolated and IRF7 translocation was analyzed by immunoblotting. 
(A–F) Data are representative of three independent experiments. Error bars represent mean ± SEM. ns, not significant.JEM VOL. 207, December 20, 2010  2803
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translocation of IRF3 and IRF7 (Fig. 3 E). Furthermore, 
consistent with the stimulatory effect of IL-1 on the pro-
duction of type I IFN (Fig. 2 D), IL-1 and CpG costimulation 
led to increased nuclear translocation of IRF7 when com-
pared with CpG stimulation alone (Fig. 3 F). Collectively, 
these data suggest that IL-1RI signaling has a tonic stimula-
tory effect in the regulation of IRFs and consequently on the 
production of type I IFN.
IL-1RI signaling modulates the ubiquitination profile of TRAF3
TRAF3, an E3 ubiquitin ligase which interacts with both 
MyD88 and TRIF, is essential for the balanced production of 
type I IFN and proinflammatory cytokines upon TLR acti-
vation (Häcker et al., 2006; Oganesyan et al., 2006; Tseng   
et al., 2010). In particular, differences in the ubiquitination pro-
file of TRAF3 have been reported to orchestrate these events. 
Although K48-linked ubiquitination leads to the degradation 
of TRAF3 and the activation of MAPKs and proinflamma-
tory cytokines, K63-linked ubiquitination is essential for the 
activation of IRFs and subsequent type I IFN production 
(Tseng et al., 2010). Because Il1r1/ BMDCs present an 
impaired activation of IRFs (Fig. 3) and production of IFN- 
(Fig. 2), we investigated the fate of TRAF3 in these cells 
upon CpG stimulation. Although the baseline expression of 
TRAF3 was higher in WT cells, TRAF3 levels were reduced 
in both WT and Il1r1/ BMDCs upon TLR9 stimulation 
(Fig. 4 A). The extent of TRAF3 degradation was very simi-
lar under each condition, as indicated by densitometric analysis 
of the bands, suggesting that IL-1RI deficiency does not 
affect the degradative K48-linked ubiquitination of TRAF3. 
Indeed, K48-linked ubiquitination was not affected in the 
absence of IL-1RI signaling (Fig. 4 B, top). In contrast, K63-
linked ubiquitination was greatly reduced in Il1r1/ as 
compared with WT BMDCs (Fig. 4 B, bottom). K63-linked 
ubiquitination in WT BMDCs was also shown in the absence 
of proteasomal inhibition, indicating that CpG induces K63 
ubiquitination  despite  the  K48-dependent  degradation  of 
TRAF3 (Fig. S3). Collectively, these results identified the 
and IFN- in response to both TLR9 (CpG) and TLR3 
[P(I:C)] stimulation as compared with those from WT mice 
(Fig. 2 B). In contrast, we observed increased levels of IL-6 
and TNF in response to CpG but not to P(I:C) stimulation 
(Fig. 2 B). Furthermore, in vitro blockade of IL-1RI signal-
ing in WT BMDCs, with either anti–IL-1RI blocking or 
anti–IL-1 neutralizing antibodies, resulted in reduced TLR9-
dependent production of IL-10 and IFN- levels and in aug-
mented levels of TNF and IL-6 (Fig. 2 C). To further elucidate 
the antiinflammatory effects of IL-1RI signaling, we stimulated 
WT BMDCs with IL-1. This stimulation led to a modest 
increase in the secretion of IL-6 and TNF without detectable 
levels of IL-10 and IFN- (Fig. 2 D, solid bars). However, 
when IL-1–pretreated cells were restimulated with CpG, 
we observed a significant reduction in the TLR9-dependent 
production of IL-6 and TNF and an increased production of 
IL-10 and IFN- (Fig. 2 D, empty bars). Collectively, these 
in vitro results further support the antiinflammatory role of 
IL-1RI signaling observed in vivo (Fig. 1), especially in the 
context of TLR stimulation.
Signaling via IL-1RI is required for the activation of IRFs
Upon TLR stimulation, the production of pro- and anti-
inflammatory cytokines is tightly regulated by the activation   
of different families of transcription factors, including NF-kB, 
MAPKs, and IRFs. In vitro activation of BMDCs from Il1r1/ 
mice by CpG led to a modest increase in the activation of 
NF-kB and NF-kB target genes compared with WT BMDCs 
(Fig. 3, A and B). More significantly, this activation resulted 
in a marked increase in the phosphorylation levels of ERK 
and a mild increase in the activation of p38 and JNK MAPKs 
(Fig. 3 C). The increase in NF-kB and MAPK activation 
probably explain the augmented production of TNF and IL-6 
by Il1r1/ BMDCs in response to TLR9 stimulation. In 
contrast, the activation and nuclear translocation of IRF3 and 
IRF7, under the same conditions, were greatly reduced in 
Il1r1/ BMDCs (Fig. 3 D). Importantly, freshly isolated 
splenocytes from Il1r1/ mice also showed reduced nuclear 
Figure 4.  IL-1RI signaling modulates the 
ubiquitination profile of TRAF3. (A) Immuno-
blot analysis of TRAF3 in total cell lysates 
from WT and Il1r1/ BMDCs stimulated with 
10 µg/ml CpG for the indicated time periods. 
Ratio expresses the densitometry analysis of 
the TRAF3 bands normalized to the expression 
of -actin. (B) TRAF3 ubiquitination assay. WT 
and Il1r1/ BMDCs were treated with the 
proteasome inhibitor MG132 for 2 h and then 
stimulated with 10 µg/ml CpG for the indicated 
time periods. Overnight immunoprecipitation 
of TRAF3 was then followed by immunoblot-
ting with anti–K48-linked ubiquitin (K48-Ub), 
anti–K63-linked ubiquitin (K63-Ub), or anti-
TRAF3. (A and B) Data are representative of 
three different experiments.2804 IL-1RI dampens DUBA | González-Navajas et al.
transcription. Finally, we determined whether DUBA is re-
sponsible for the reduced production of IL-10 and IFN- in 
Il1r1/ BMDCs. DUBA knockdown by siRNA transfec-
tion in Il1r1/ BMDCs (Fig. 5 D) resulted in significantly 
increased IL-10 and IFN- production and decreased secre-
tion of IL-6, but not TNF, in CpG-stimulated Il1r1/ 
BMDCs (Fig. 5 E).
Our findings suggest that IL-1RI signaling positively reg-
ulates TLR-dependent type I IFN production. In the absence 
of IL-1 signaling, DUBA expression levels are increased and, 
therefore, the cleavage of K63-linked polyubiquitin chains of 
TRAF3, upon TLR stimulation, is facilitated. This effect re-
sults in reduced activation of TRAF3 and, consequently, di-
minished type I IFN and IL-10 responses.
IL-1 is an endogenous cytokine that utilizes TLR signaling 
pathways, suggesting its close relation to innate defense net-
works against microbial threats. By regulating DUBA levels, 
IL-1RI signaling equilibrates the pro- and antiinflammatory 
cytokine production in response to exogenous microbial TLR 
stimulation. Our results have uncovered new antiinflamma-
tory and protective properties of this well-known and pleio-
tropic proinflammatory cytokine. They also reveal a novel 
mechanism by which IL-1RI signaling restrains TLR-mediated 
inflammatory responses.
The therapeutic potential of blocking IL-1RI signaling 
has been recognized for >20 yr, resulting in the generation   
of numerous compounds. The development of IL-1RA as a 
therapy for sepsis, an overwhelming inflammatory response 
to infection, was unsuccessful. However, patients suffering from 
sterile inflammatory diseases, such as rheumatoid arthritis and 
role of IL-1RI signaling in the activation of TRAF3 and ex-
plain why Il1r1/ BMDCs have lower production of IFN- 
and IL-10 but increased or normal production of proinflam-
matory cytokines under the experimental conditions specified 
in this section.
DUBA inhibits type I IFN production in the absence  
of IL-1RI signaling
DUBs are proteases that cleave ubiquitin linkages. DUBA, a 
member of the ovarian tumor (OTU) domain–containing cys-
teine protease superfamily, was shown to suppress the type I 
IFN-dependent innate immune response by cleaving the K63 
polyubiquitin chain on TRAF3 (Kayagaki et al., 2007). Cleav-
age resulted in the dissociation of TRAF3 from the downstream 
signaling complex and disruption of type I IFN production. 
To study the role of DUBA in the differential ubiquitination 
of TRAF3, we stimulated BMDCs from WT and Il1r1/ 
mice with CpG and assayed its impact on DUBA protein 
levels. As shown in Fig. 5 A, CpG induces higher levels of 
DUBA protein in Il1r1/ as compared with WT BMDCs. 
Importantly, steady-state levels of DUBA protein were in-
creased in BMDCs (Fig. 5 A) as well as in freshly isolated 
splenocytes from Il1r1/ mice (Fig. 5 B). It is of note that 
DUBA levels were not increased in splenocytes from Tlr3/ 
or Tlr9/ mice (Fig. S4), indicating that the dysregulation of 
DUBA expression is not a common characteristic in all TLR-
deficient cells. Consistent with the protein data, Duba mRNA 
levels were increased in freshly isolated splenocytes and 
mesenteric LN-derived cells from Il1r1/ mice (Fig. 5 C), sug-
gesting that IL-1RI signaling negatively regulates DUBA 
Figure 5.  DUBA inhibits type I IFN production by Il1r1/ BMDCs. (A) Immunoblot analysis of DUBA in total cell lysates from WT and Il1r1/ 
BMDCs stimulated with 10 µg/ml CpG for the indicated time periods. (B) Immunoblot analysis of DUBA expression in total cell lysates from freshly iso-
lated splenocytes from WT and Il1r1/ mice. (C) Quantitative PCR analysis of Duba mRNA expression in freshly isolated splenocytes and mesenteric  
LN-derived cells from WT and Il1r1/ mice. (D) Immunoblot analysis of DUBA expression in total cell lysates from Il1r/ BMDCs transfected with 0.5 µM 
of either control (Ctrl) or DUBA siRNAs. (E) Pro- and antiinflammatory cytokine production in Il1r1/ BMDCs after DUBA knockdown. Il1r1/ BMDCs were 
transfected as described in D. 24 h after transfection, cells were stimulated with 10 µg/ml CpG oligonucleotides for an additional 24 h and cytokine pro-
duction was determined by ELISA. (A–E) Data are representative of three different experiments. Error bars represent mean ± SEM. *, P < 0.05; **, P < 0.01.JEM VOL. 207, December 20, 2010  2805
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using Superscript III First-Strand system (Invitrogen). Quantitative real-
time PCR was performed on an AB7300 (Applied Biosystems) using 
SYBR Green PCR Master Mix (Applied Biosystems). GAPDH expression 
was used as internal reference. RT-PCR primers for specific target genes 
(Table S1) were designed based on their reported sequences and synthe-
sized by IDT Technologies.
Measurement of cytokine levels in colonic tissue. Colonic explants 
were  obtained  and  cultured  as  previously  described  (Abe  et  al.,  2007;   
González-Navajas et al., 2010). After 24–36 h of culture, cytokine levels from the   
supernatants were measured using sandwich ELISAs for IL-1, IL-6, TNF,   
and IL-10 (eBioscience).
IFN- ELISA. Analysis of IFN- levels was performed as previously de-
scribed (Weinstein et al., 2000). In brief, 96-well plates were coated over-
night with 1 µg/ml of rat anti–mouse IFN- monoclonal antibody (Abcam). 
The plates were then blocked for 2 h before the addition of culture superna-
tants or recombinant IFN- standard (Millipore). After incubation (over-
night at 4°C or 2 h at 37°C), plates were washed and 50 U/ml of rabbit 
anti–mouse IFN- (PBL) was added per well. The plates were incubated for 
60 min at room temperature, washed, and then 3 µg/ml anti–rabbit IgG-
HRP was added per well. The bound peroxidase was finally detected by the 
addition of TMB substrate (Sigma-Aldrich).
In vitro stimulation of BMDCs. BMDCs from WT and Il1r1/ mice 
were prepared as previously described (Lutz et al., 1999; Datta et al., 2003). 
CD11c+ cells were then isolated by positive selection using MACS Micro-
beads, according to the manufacturer’s protocol (Miltenyi Biotec). For cyto-
kine production, BMDCs were incubated with 10 µg/ml CpG-ODN or 
20 µg/ml Poly(I:C) and the culture supernatants were collected after 24 h.
For neutralization studies, WT BMDCs were incubated with 2 µg/ml 
anti-IL1RI or 5 µg/ml anti–IL-1 antibodies for 2 h. Cells were then stimu-
lated with 10 µg/ml CpG-ODN for 24 h.
For pretreatment studies, WT BMDCs were cultured in the presence of 
1 or 10 ng/ml rmIL-1 for 12 h. After collection of the supernatants, cells 
were washed and restimulated with CpG-ODN for 24 h.
For  immunoblot  analysis,  BMDCs  were  stimulated  with  10  µg/ml 
CpG-ODN for different periods of time. Cells were then collected and total 
cell lysates were obtained using RIPA buffer (Sigma-Aldrich). For some ex-
periments, nuclear and cytosolic protein fractions were separated as previ-
ously described (Lee et al., 2000, 2006).
EMSA. Translocation of activated NF-B into the nucleus was measured by 
EMSA using consensus NF-B oligonucleotides (Santa Cruz Biotechnol-
ogy, Inc.) as previously described (Lee et al., 2000, 2006).
Immunoprecipitation and ubiquitination assays. WT and Il1r1/ 
BMDCs were prepared as described in In vitro stimulation of BMDCs and 
cultured with 10 µM of the proteasome inhibitor MG132 for 2 h. Cells 
were then stimulated with 10 µg/ml CpG-ODN for different periods of 
time and total cell lysates were prepared in lysis buffer containing 20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM EDTA, 1% (vol/vol) Triton   
X-100, 1% (vol/vol) deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 
20 µg/ml aprotinin, and 20 mM N-ethylmaleimide. Proteins (200 µg per 
sample) were boiled at 95°C in the presence of 0.1% SDS to remove noncova-
lently associated proteins. Samples were then immunoprecipitated overnight 
with constant mixing at 4°C with 2 µg/ml TRAF3 antibody (Santa Cruz 
Biotechnology, Inc.) and protein A–agarose beads (10 µl per 100 µl of total 
lysate). After extensive washing with lysis buffer, the immunocomplexes 
and any noncovalently bound proteins were dissociated by boiling in 4X 
LDS sample buffer (Invitrogen) and subjected to SDS page, followed by 
immunoblotting with rabbit anti-ubiquitin Lys63- (clone Apu3) or anti-
ubiquitin Lys48 (clone Apu2)-specific antibodies (Miltenyi Biotec) and a 
light chain–specific anti–rabbit IgG-HRP as secondary antibody (Jackson 
ImmunoResearch Laboratories).
autoinflammatory syndromes, systemic onset juvenile idio-
pathic arthritis, and gout were shown to benefit from blocking 
IL-1RI signaling (Bresnihan et al., 1998; Emsley et al., 2005; 
Pascual et al., 2005; Dinarello, 2009). Our findings may help 
to explain these clinical observations and suggest that IL-1R 
blockade can be harmful in certain infections or in nonsterile 
inflammatory conditions.
MATERIALS AND METHODS
Mice. 6–10-wk-old mice were used for all the experimental procedures. 
Specific pathogen-free (SPF) C57BL/6 (B6 and WT) mice were purchased 
from Harlan Sprague Dawley Inc. Il1r1/ mice on the B6 background (The 
Jackson Laboratory) were bred in our animal facility under SPF conditions. 
Tlr3/ and Tlr9/ mice on the B6 background were provided by S. Akira 
(Osaka University, Osaka, Japan). All experimental procedures were approved 
by the University of California, San Diego Institutional Animal Care and 
Use Committee.
Reagents. 1018 CpG-ODN (5-TGACTGTGAACGTTCGAGATGA-3) 
was purchased from TriLink Biotechnologies (Katakura et al., 2005; Abe 
et al., 2007). Synthetic analogue of dsRNA (Poly(I:C)) was purchased from 
InvivoGen. All TLR ligands were LPS free. DSS was purchased from MP 
Biomedicals. rmIFN- was purchased from Millipore. rmIL-1 was pur-
chased from BD. Anakinra was obtained from Amgen.
Antibodies. Anti–mouse IL-1 (clone B122) and anti–mouse IL-1 (clone 
ALF-161) antibodies were purchased from eBioscience, anti–mouse CD121a 
(IL-1 receptor, type I; clone 35F5) antibody from BD, anti-IRF3, anti-IRF7, 
and anti-OTUD5 (DUBA) antibodies from Abcam, anti-ERK, anti–p-ERK, 
anti-p-p38, and anti–p-JNK antibodies from Cell Signaling Technolo-
gies, anti-TRAF3 antibody from Santa Cruz Biotechnology, Inc., anti-
ubiquitin Lys63-specific (clone Apu3) and anti-ubiquitin Lys48-specific 
(clone Apu2) antibodies from Millipore, and anti–-actin antibody from 
Sigma-Aldrich.
DSS-induced colitis. WT (B6) and Il1r1/ mice were given 2% DSS 
(wt/vol) dissolved in sterile water ad libitum for 7 d. Groups of mice were 
treated with 10 µg CpG-ODN per mouse i.p., 2 h before DSS administra-
tion. The DAI score, combining weight loss and bleeding, was determined 
as previously described (Rachmilewitz et al., 2004; Katakura et al., 2005; 
Abe et al., 2007).
Histological evaluation. Preparation, H&E staining, and histological eval-
uation of colonic tissues was performed as described in our previous publica-
tions (Katakura et al., 2005; González-Navajas et al., 2010).
Anakinra  treatment. WT mice (B6) were exposed to 2% DSS in the 
drinking water for 7 d as previously described (Rachmilewitz et al., 2004; 
Katakura et al., 2005; Abe et al., 2007). Starting 1 d before DSS exposure, 
mice were treated with two daily injections s.c. of anakinra (1 mg/mouse) or 
saline solution (vehicle). Mice were monitored daily for body weight loss 
and signs of intestinal inflammation.
rmIFN- treatment. Il1r1/ mice were treated with daily injections of 
rmIFN- (1,000 U/mouse) or vehicle i.p. during DSS exposure as described 
in DSS-induced colitis. Mice were monitored daily for body weight loss and 
signs of intestinal inflammation.
Isolation of RNA and quantitative RT-PCR. The isolation of RNA 
and quantitative RT-PCR were performed as described in our previous 
publications (Katakura et al., 2005; González-Navajas et al., 2010). In brief, 
isolation of RNA was performed using RNeasy Mini kit (QIAGEN). After 
isolation, RNA was treated with DNase I (Invitrogen) to digest contami-
nating DNA. Synthesis of cDNA by reverse transcription was performed 2806 IL-1RI dampens DUBA | González-Navajas et al.
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Gene  silencing  by  siRNA.  Negative  control  siRNA  and  OTUD5 
(DUBA) siRNA were purchased from Santa Cruz Biotechnology, Inc. 
DUBA siRNA sequences, consisting of a pool of three target-specific 19–
25-nt siRNA duplexes, are specified in Table S2. Transfection of siRNA 
was performed by electroporation using a mouse DC nucleofection kit and 
a Nucleofector II device (Lonza) as previously described (González-Navajas 
et al., 2010).
Statistical analysis. Values are displayed as mean ± SD. Statistical dif-
ferences between groups were analyzed using the nonparametric Mann-
Whitney U test for quantitative data. For the comparison of survival curves, the 
nonparametric log-rank test was performed. All the p-values are two-tailed, 
and p-values <0.05 were considered significant. All calculations were per-
formed using Prism 4.0 software (GraphPad Software, Inc.).
Online supplemental material. Fig. S1 shows that anakinra treatment ex-
acerbates intestinal inflammation after DSS injury. Fig S2 shows that treat-
ment with rmIFN- ameliorates colitis in Il1r1/ mice. Fig. S3 shows that 
CpG triggers the K63-linked ubiquitination of TRAF3 in the absence of 
proteasomal inhibition. Fig. S4 shows that DUBA is not overexpressed in 
Tlr32/2 or Tlr92/2 mice. Table S1 shows oligonucleotides used for quanti-
tative PCR analysis. Table S2 shows siRNA duplexes used for DUBA   
silencing experiments. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20101326/DC1.
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